| Year |
Citation |
Score |
| 2020 |
Ivanidze J, Skafida M, Pandya S, Patel D, Osborne JR, Raj A, Gupta A, Henchcliffe C, Dyke JP. Molecular Imaging of Striatal Dopaminergic Neuronal Loss and the Neurovascular Unit in Parkinson Disease. Frontiers in Neuroscience. 14: 528809. PMID 33071729 DOI: 10.3389/Fnins.2020.528809 |
0.308 |
|
| 2020 |
Batra JS, Niaz MJ, Whang YE, Sheikh A, Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM, Osborne J, Bander NH, Tagawa ST. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer. Urologic Oncology. PMID 32600929 DOI: 10.1016/J.Urolonc.2020.05.028 |
0.351 |
|
| 2020 |
Niaz MJ, Batra JS, Walsh RD, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM, Osborne JR, Bander NH, Tagawa ST. Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 ( Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. The Oncologist. PMID 31999003 DOI: 10.1634/Theoncologist.2020-0028 |
0.359 |
|
| 2020 |
Vlachostergios PJ, Goswami S, Niaz MJ, Thomas C, Christos PJ, Osborne J, Vallabhajosula S, Molina AM, Sternberg CN, Singh S, Tan A, Patel A, Nanus DM, Bander NH, Tagawa ST. Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 45-45. DOI: 10.1200/Jco.2020.38.6_Suppl.45 |
0.313 |
|
| 2020 |
Tagawa ST, Osborne J, Niaz MJ, Vallabhajosula S, Vlachostergios PJ, Thomas C, Molina AM, Sternberg CN, Singh S, Fernandez E, Babich J, Nanus DM, Ballman KV, Bander NH. Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 114-114. DOI: 10.1200/Jco.2020.38.6_Suppl.114 |
0.361 |
|
| 2020 |
Tagawa ST, Osborne J, Fernandez E, Thomas C, Niaz MJ, Ciriaco A, Vallabhajosula S, Vlachostergios PJ, Molina AM, Sternberg CN, Singh S, Babich J, Nanus DM, Ballman KV, Bander NH. Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 5560-5560. DOI: 10.1200/Jco.2020.38.15_Suppl.5560 |
0.349 |
|
| 2020 |
Tagawa ST, Osborne J, Thomas C, Fernandez E, Niaz MJ, Vallabhajosula S, Vlachostergios P, Molina AM, Sternberg C, Singh S, Patel A, Tan A, Babich J, Nanus DM, Ballman K, et al. Abstract CT122: Phase I dose-escalation study of prostate-specific membrane antigen (PSMA)-targeted alpha emitter225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC) Tumor Biology. DOI: 10.1158/1538-7445.Am2020-Ct122 |
0.374 |
|
| 2020 |
Sun M, Niaz M, Thomas C, Schaap A, Lacuna K, Vlachostergios P, Christos P, Molina AM, Nanus DM, Sternberg CN, Osborne J, Bander NH, Tagawa ST. Abstract 6511: Androgen receptor (AR) genomic alterations and clinical outcome with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy Cancer Research. 80: 6511-6511. DOI: 10.1158/1538-7445.Am2020-6511 |
0.391 |
|
| 2020 |
Niaz MJ, Skafida M, Osborne J, Nanus D, Molina A, Thomas C, Vallabhajosula S, Christos P, Bander N, Tagawa S. Pd16-11 Comparison Of Prostate-Specific Membrane Antigen (Psma)-Targeted Radionuclide Therapy (Trt) With Lutetium-177 (177Lu) Via Antibody J591 Vs Small Molecule Ligand Psma-617 The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000859.011 |
0.316 |
|
| 2019 |
Ivanidze J, Roytman M, Sasson A, Skafida M, Fahey TJ, Osborne JR, Dutruel SP. Molecular imaging and therapy of somatostatin receptor positive tumors. Clinical Imaging. 56: 146-154. PMID 31121520 DOI: 10.1016/J.Clinimag.2019.04.006 |
0.314 |
|
| 2019 |
Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, et al. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. Jama Oncology. PMID 31120534 DOI: 10.1001/Jamaoncol.2019.0826 |
0.328 |
|
| 2019 |
Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, Osborne J, Beltran H, Molina AM, Goldsmith SJ, Bander NH, Nanus DM. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ( Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. PMID 31012963 DOI: 10.1002/Cncr.32072 |
0.376 |
|
| 2019 |
Tagawa ST, Niaz MJ, Osborne J, Vallabhajosula S, Beltran H, Harshman LC, Nanus DM, Molina AM, Faltas BM, Hackett A, Gracey L, Sreekumar J, Babich J, Ballman KV, Bander NH. Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.7_Suppl.Tps339 |
0.367 |
|
| 2019 |
Vlachostergios PJ, Niaz MJ, Mosallaie SA, Christos PJ, Hackett A, Osborne JR, Jhanwar Y, Gracey L, Molina AM, Nanus DM, Bander NH, Tagawa ST. Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT). Journal of Clinical Oncology. 37: 5013-5013. DOI: 10.1200/Jco.2019.37.15_Suppl.5013 |
0.352 |
|
| 2019 |
Tagawa ST, Osborne JR, Hackett A, Niaz MJ, Cooley V, Christos P, Vlachostergios PJ, Thomas C, Gracey L, Beltran H, Molina AM, Nanus DM, Babich J, Vallabhajosula S, Sartor O, et al. Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC) Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz248.006 |
0.347 |
|
| 2018 |
Ramirez-Fort MK, Mahase SS, Osborne JR, Lange CS. Theragnostic Target, Prostate-Specific Membrane Antigen-Also Specific for Nonprostatic Malignancies. International Journal of Radiation Oncology, Biology, Physics. 101: 646-649. PMID 29893276 DOI: 10.1016/J.Ijrobp.2018.03.061 |
0.335 |
|
| 2017 |
Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW, Lewis JS, Solomon SB, Osborne JR, Veach D, Sawyers CL, et al. Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. Jama Oncology. e173588. PMID 29121144 DOI: 10.1001/Jamaoncol.2017.3588 |
0.362 |
|
| 2017 |
Osborne JR, Kalidindi TM, Punzalan BJ, Gangangari K, Spratt DE, Weber WA, Larson SM, Pillarsetty NVK. Erratum to: Repeatability of [(68)Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 28695370 DOI: 10.1007/S11307-017-1104-8 |
0.354 |
|
| 2017 |
Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD, Aldubayan S, Khani F, Karir B, Kim E, Chimene-Weiss J, ... ... Osborne JR, et al. Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Cancer Discovery. PMID 28515055 DOI: 10.1158/2159-8290.Cd-16-0960 |
0.358 |
|
| 2017 |
Soliman M, Taunk NK, Simons RE, Osborne JR, Kim MM, Szerlip NJ, Spratt DE. Anatomic and functional imaging in the diagnosis of spine metastases and response assessment after spine radiosurgery. Neurosurgical Focus. 42: E5. PMID 28041315 DOI: 10.3171/2016.9.Focus16350 |
0.497 |
|
| 2016 |
Spratt DE, Chen YW, Mahal BA, Osborne JR, Zhao SG, Morgan TM, Palapattu G, Feng FY, Nguyen PL. Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. European Urology Focus. 2: 532-539. PMID 28723519 DOI: 10.1016/J.Euf.2016.03.010 |
0.339 |
|
| 2016 |
Das DK, Naidoo M, Ilboudo A, Park JY, Ali T, Krampis K, Robinson BD, Osborne JR, Ogunwobi OO. miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin. Experimental Cell Research. PMID 27693493 DOI: 10.1016/J.Yexcr.2016.09.021 |
0.362 |
|
| 2016 |
Spratt DE, Osborne J, Zumsteg ZS, Rebiez K, Leeman JE, Rivera A, Zelefsky MJ. Radium-223 Outcomes After Multiple Lines of Metastatic Castration-Resistant Prostate Cancer Therapy in Clinical Practice: Implication of Pretreatment Spinal Epidural Disease. International Journal of Radiation Oncology, Biology, Physics. 96: E224. PMID 27674109 DOI: 10.1016/J.Ijrobp.2016.06.1152 |
0.318 |
|
| 2016 |
Spratt DE, Osborne JR, Zumsteg ZS, Rebeiz K, Leeman J, Rivera A, Morris MJ, Zelefsky MJ. Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease. Prostate Cancer and Prostatic Diseases. PMID 27112529 DOI: 10.1038/Pcan.2016.14 |
0.33 |
|
| 2016 |
Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, Chalasani S, Weber WA, Spratt DE, Veach DR, Bander NH, Larson SM, Zanzonico PB, Osborne JR. Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. Ejnmmi Research. 6: 7. PMID 26801327 DOI: 10.1186/S13550-016-0164-0 |
0.358 |
|
| 2016 |
Spratt D, Chen Y, Mahal B, Osborne J, Zhao S, Morgan T, Palapattu G, Feng F, Nguyen P. Mp37-07 Individual Patient Data Analysis In Randomized Clinical Trials: Impact Of Race On Prostate Cancer Outcomes The Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1684 |
0.322 |
|
| 2015 |
Ilboudo A, Chouhan J, McNeil BK, Osborne JR, Ogunwobi OO. PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer? International Journal of Environmental Research and Public Health. 13. PMID 26703666 DOI: 10.3390/Ijerph13010012 |
0.314 |
|
| 2015 |
Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gonen M, Heller G, Loda M, Nanus DM, ... ... Osborne J, et al. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26175541 DOI: 10.1158/1078-0432.Ccr-15-0552 |
0.367 |
|
| 2015 |
Spratt DE, Osborne JR. Disparities in castration-resistant prostate cancer trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1101-3. PMID 25691679 DOI: 10.1200/Jco.2014.58.1751 |
0.357 |
|
| 2014 |
Fung EK, Cheal SM, Chalasani S, Fareedy SB, Otto B, Punzalan B, Humm JL, Bander NH, Osborne JR, Larson SM, Zanzonico PB. TU-F-12A-01: Quantitative Non-Linear Compartment Modeling of 89Zr- and 124I- Labeled J591 Monoclonal Antibody Kinetics Using Serial Non-Invasive Positron Emission Tomography Imaging in a Pre-Clinical Human Prostate Cancer Mouse Model. Medical Physics. 41: 480. PMID 28036735 DOI: 10.1118/1.4889356 |
0.363 |
|
| 2014 |
Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, Solnes L, Maresca KP, Armor T, Joyal JL, Crummet R, Stubbs JB, Goldsmith SJ. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 1791-8. PMID 25342385 DOI: 10.2967/Jnumed.114.140426 |
0.354 |
|
| 2014 |
Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, et al. ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 41: 2093-105. PMID 25143071 DOI: 10.1007/S00259-014-2830-7 |
0.383 |
|
| 2014 |
Spratt DE, Gavane S, Tarlinton L, Fareedy SB, Doran MG, Zelefsky MJ, Osborne JR. Utility of FDG-PET in clinical neuroendocrine prostate cancer. The Prostate. 74: 1153-9. PMID 24913988 DOI: 10.1002/Pros.22831 |
0.33 |
|
| 2014 |
Osborne JR, Green DA, Spratt DE, Lyashchenko S, Fareedy SB, Robinson BD, Beattie BJ, Jain M, Lewis JS, Christos P, Larson SM, Bander NH, Scherr DS. A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. The Journal of Urology. 191: 1439-45. PMID 24135437 DOI: 10.1016/J.Juro.2013.10.041 |
0.369 |
|
| 2014 |
Chalasani S, Fareedy S, Lindgren-Belal S, Spratt D, Robinson B, Osborne J, Bander N, Scherr D. Mp51-14 A Comparison Of 111In-J591 Spect With 89Zr-J591 Pet Imaging For Prostate Cancer Patients. The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1670 |
0.388 |
|
| 2014 |
Spratt DE, Zelefsky MJ, Fareedy S, Lindgren S, Osborne JR. Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.772 |
0.38 |
|
| 2014 |
Spratt D, Fareedy S, Lindgren S, Robinson B, Larson S, Lewis J, Bander N, Scherr D, Osborne J. Molecular Imaging for Localized Prostate Cancer: Analysis of 2 Prospective Phase 0 Trials of PSMA Targeted Immuno-PET and -SPECT, and Implications for the Radiation Oncologist International Journal of Radiation Oncology*Biology*Physics. 90: S208. DOI: 10.1016/J.Ijrobp.2014.05.770 |
0.332 |
|
| 2013 |
Akhtar NH, Osborne J, Christos PJ, Vallabhajosula S, Goldsmith SJ, Kahn R, Ecker C, Beltran H, Morris MJ, Milowsky MI, Bander NH, Nanus DM. Phase II trial of (177)lutetium radiolabeled anti-PSMA antibody J591 ((177)Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 121. PMID 28136812 DOI: 10.1200/Jco.2013.31.6_Suppl.121 |
0.325 |
|
| 2013 |
Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5182-91. PMID 23714732 DOI: 10.1158/1078-0432.Ccr-13-0231 |
0.397 |
|
| 2013 |
Akhtar NH, Osborne JR, Fareedy SB, Tagawa ST. PSMA-targeted dendrimers: a patent evaluation (WO2012078534). Expert Opinion On Therapeutic Patents. 23: 665-8. PMID 23581819 DOI: 10.1517/13543776.2013.789501 |
0.378 |
|
| 2013 |
Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate-specific membrane antigen-based imaging. Urologic Oncology. 31: 144-54. PMID 22658884 DOI: 10.1016/J.Urolonc.2012.04.016 |
0.363 |
|
| 2013 |
Tagawa ST, Akhtar NH, Christos PJ, Osborne J, Vallabhajosula S, Freedy S, Goldsmith SJ, Nanus DM, Bander NH. Noninvasive measurement of prostate-specific membrane antigen (PSMA) expression with radiolabeled J591 imaging: A prognostic tool for metastatic castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 31: 11081-11081. DOI: 10.1200/Jco.2013.31.15_Suppl.11081 |
0.372 |
|
| 2013 |
Akhtar NH, Osborne J, Nanus DM, Vallabhajosula S, Goldsmith SJ, Bander NH, Tagawa ST. Abstract 4696: Non-invasive measurement of prostate-specific membrane antigen (PSMA) expression with radiolabeled J591 imaging: a promising biomarker for PSMA-based radioimmunotherapy. Cancer Research. 73: 4696-4696. DOI: 10.1158/1538-7445.Am2013-4696 |
0.392 |
|
| 2013 |
Green D, Fareedy SB, Osborne JR, Robinson BD, Goldenberg S, Tewari A, Herman M, Bander N, Scherr DS. 679 A Pilot Study Of Zr89-J591 Positron Emission Tomography (Pet) Imaging In Men With Prostate Cancer Undergoing Radical Prostatectomy The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.234 |
0.365 |
|
| 2013 |
Green D, Osterberg C, Osborne JR, Nikolopoulou A, Vallabhajosula S, Goldsmith SJ, Robinson BD, Goldenberg S, Babich J, Scherr DS. 2200 A Phase 1 Pilot Study Of 99Mtc-Mip-1404 Single Photon Emission Computed Tomography (Spect)/Ct Imaging In Men With Prostate Cancer Undergoing Radical Prostatectomy The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2109 |
0.369 |
|
| 2012 |
Osborne J, Akhtar NH, Vallabhajosula S, Nikolopoulou A, Maresca KP, Hillier SM, Joyal JL, Crummet R, Armor T, Tagawa ST, Nanus DM, Goldsmith SJ, Babich JW. Tc-99m labeled small-molecule inhibitors of prostate-specific membrane antigen (PSMA): New molecular imaging probes to detect metastatic prostate adenocarcinoma (PC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 173. PMID 27968110 DOI: 10.1200/Jco.2012.30.5_Suppl.173 |
0.329 |
|
| 2012 |
Kosuri S, Akhtar NH, Smith M, Osborne JR, Tagawa ST. Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy. Advances in Urology. 2012: 921674. PMID 22693495 DOI: 10.1155/2012/921674 |
0.366 |
|
| 2012 |
Tagawa ST, Vallabhajosula S, Akhtar NH, Osborne J, Beltran H, Saran A, Mileo G, Ecker C, Goldsmith SJ, Nanus DM, Bander NH. Abstract 748: Phase I trial of fractionated-dose177Lutetium radiolabeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) in patients with metastatic castration-resistant prostate cancer (metCRPC) Cancer Research. 72: 748-748. DOI: 10.1158/1538-7445.Am2012-748 |
0.304 |
|
| 2012 |
Deh K, Chandrasekaran S, Fareedy S, Osborne J. Abstract A77: Preclinical multimodality imaging of metastatic prostate cancer xenograft models with 89Zr-J591. Cancer Epidemiology, Biomarkers & Prevention. 21. DOI: 10.1158/1055-9965.Disp12-A77 |
0.404 |
|
| 2012 |
Tagawa ST, Akhtar N, Osborne J, Vallabhajosula S, Beltran H, Saran A, Mileo G, Goldsmith SJ, Nanus DM, Bander NH. 952 Anti-Prostate Specific Membrane Antigen (Psma)-Based Radioimmunotherapy For Metastatic Castration-Resistant Prostate Cancer (Crpc): A Decade Of Experience With Radiolabeled (Rl)-J591 The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1050 |
0.363 |
|
| 2011 |
Tagawa ST, Hahn NM, Vaena DA, Quinn DI, Kelly WK, Christos PJ, Osborne J, Vallabhajosula S, Nadeau K, Mileo G, Tyrell L, Saran A, Ecker C, Beltran H, Goldsmith SJ, et al. Radiolabeled anti-prostate specific membrane antigen (PSMA) monoclonal antibody J591 ((177)Lu-J591) for nonmetastatic castration-resistant prostate cancer (CRPC): A randomized phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS193. PMID 28023072 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps193 |
0.373 |
|
| 2011 |
Akhtar NH, Nanus DM, Vallabhajosula S, Osborne J, Beltran H, Tyrell L, Nadeau K, Saran A, Mileo G, Goldsmith SJ, Bander NH, Tagawa ST. Radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e15186. PMID 28020956 DOI: 10.1200/Jco.2011.29.15_Suppl.E15186 |
0.345 |
|
| 2010 |
Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, Cook JB, Larson S. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 543-50. PMID 20237034 DOI: 10.2967/Jnumed.108.060459 |
0.303 |
|
| 2010 |
Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM, Bander NH. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 116: 1075-1083. PMID 20127956 DOI: 10.1002/Cncr.24795 |
0.39 |
|
| 2010 |
Tagawa ST, Osborne J, Christos PJ, Vallabhajosula S, Petrillo K, Nadeau K, Tyrell L, Beltran H, Goldsmith SJ, Nanus DM. A randomized phase II trial of 177lu radiolabeled monoclonal antibody J591 (177Lu-J591) and ketoconazole in patients (pts) with high-risk castrate biochemically relapsed prostate cancer (PC) after local therapy. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps248 |
0.384 |
|
| 2010 |
Beltran H, Vallabhajosula S, Kelly WK, Whang YE, Osborne J, Petrillo K, Goldsmith SJ, Bander NH, Nanus DM, Tagawa ST. Phase I dose-escalation study of docetaxel/predisone and fractionated 177Lu-J591 for metastatic castrate-resistant prostate cancer (metCRPC). Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps247 |
0.375 |
|
| 2010 |
Tagawa ST, Vallabhajosula S, Osborne J, Goldsmith SJ, Petrillo K, Tyrell L, Dhillon GS, Beltran H, Bander NH, Nanus DM. Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC). Journal of Clinical Oncology. 28: 4667-4667. DOI: 10.1200/Jco.2010.28.15_Suppl.4667 |
0.358 |
|
| 2005 |
Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Research. 65: 9080-8. PMID 16204083 DOI: 10.1158/0008-5472.Can-05-0436 |
0.363 |
|
| 2004 |
Yu CR, Power J, Barnea G, O'Donnell S, Brown HE, Osborne J, Axel R, Gogos JA. Spontaneous neural activity is required for the establishment and maintenance of the olfactory sensory map. Neuron. 42: 553-66. PMID 15157418 DOI: 10.1016/S0896-6273(04)00224-7 |
0.688 |
|
| 2004 |
Eggan K, Baldwin K, Tackett M, Osborne J, Gogos J, Chess A, Axel R, Jaenisch R. Mice cloned from olfactory sensory neurons. Nature. 428: 44-9. PMID 14990966 DOI: 10.1038/Nature02375 |
0.668 |
|
| 2000 |
Gogos JA, Osborne J, Nemes A, Mendelsohn M, Axel R. Genetic ablation and restoration of the olfactory topographic map. Cell. 103: 609-20. PMID 11106731 DOI: 10.1016/S0092-8674(00)00164-1 |
0.672 |
|
| Show low-probability matches. |